LivaNova PLC (LIVN)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Cardiopulmonary	785.39M	683.51M	604.11M	514.20M	482.98M
Cardiopulmonary Growth	14.90%	13.14%	17.49%	6.46%	8.11%
Neuromodulation	592.81M	554.22M	519.71M	476.99M	456.17M
Neuromodulation Growth	6.96%	6.64%	8.96%	4.56%	28.70%
Other	9.86M	15.70M	29.72M	30.61M	40.76M
Other Growth	-37.23%	-47.17%	-2.91%	-24.88%	-55.09%
Advanced Circulatory Support	-	-	-	-	55.46M
Advanced Circulatory Support Growth	-	-	-	-	31.04%
Total	1.39B	1.25B	1.15B	1.02B	1.04B
Total Growth	10.74%	8.66%	12.89%	-1.31%	10.82%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
United States	739.57M	695.08M	635.04M	571.56M	571.30M
United States Growth	6.40%	9.45%	11.11%	0.05%	21.91%
Rest of World	379.30M	338.32M	303.71M	271.45M	262.54M
Rest of World Growth	12.11%	11.40%	11.89%	3.39%	-3.56%
Europe (Excluding United Kingdom)	213.28M	171.13M	173.29M	146.50M	165.72M
Europe (Excluding United Kingdom) Growth	24.63%	-1.25%	18.29%	-11.60%	1.26%
United Kingdom	55.90M	48.90M	41.50M	32.30M	35.80M
United Kingdom Growth	14.31%	17.83%	28.48%	-9.78%	20.54%
Total	1.39B	1.25B	1.15B	1.02B	1.04B
Total Growth	10.74%	8.66%	12.89%	-1.31%	10.82%

Data Source: S&P Global Market Intelligence Last updated: May 6, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 25, 2026

Data Sources Report a data error